Predict your next investment

Venture Capital
proquestvc.com

See what CB Insights has to offer

Investments

104

Portfolio Exits

32

Funds

4

About ProQuest Investments

ProQuest Investments is a healthcare-focused venture capital firm with locations in Princeton, NJ, San Diego, CA, and Montreal, Canada. It has $900 million under management. It invests in companies seeking financings ranging from seed to late-stage.

ProQuest Investments Headquarter Location

90 Nassau Street Fifth Floor

Princeton, New Jersey, 08542,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest ProQuest Investments News

Exagen Appoints Wendy Johnson to Board of Directors

Sep 25, 2020

Exagen Appoints Wendy Johnson to Board of Directors Additional independent board member will also serve on Audit Committee SAN DIEGO, Sept. 23, 2020 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, is proud to announce the addition of Ms. Wendy S. Johnson as an additional independent member to its Board of Directors, effective October 1, 2020. Ms. Johnson will also serve on the Audit Committee. “We are excited to have added Ms. Wendy Johnson to our Board of Directors,” said Ron Rocca, Exagen’s President and Chief Executive Officer. “Her experience and knowledge in the healthcare industry will be invaluable for the next phase of Exagen’s growth. Our corporate culture of being patient-focused and discovery-driven starts with our Board of Directors and extends out to every member of Exagen. The announcement of Ms. Johnson joining our Board of Directors underscores Exagen’s commitment to delivering on our promise.” Ms. Johnson has a distinguished career in healthcare performing various roles integral to corporate growth. She is currently the Chief Operating Officer of Reneo Pharmaceuticals where she is responsible for day-to-day operations, and was instrumental in setting up the company’s UK corporate entity. Ms. Johnson was previously the Interim Chief Operating Officer of AmpliPhi Biosciences Corporation from September 2014 to January 2017, and a member of its board of directors from May 2014 until its merger with C3J Therapeutics (Armata Pharmaceuticals) in May 2019. From 2005 to January 2014, Ms. Johnson served as a venture partner at ProQuest Investments, a venture capital firm. From 2006 to January 2014, Ms. Johnson served as the President and Chief Executive Officer of Aires Pharmaceuticals, a ProQuest portfolio company, until its sale to MAST Therapeutics in 2014. Prior to joining ProQuest, she held senior business and corporate development positions at Salmedix Inc., WomenFirst Healthcare, Prizm Pharmaceuticals (Selective Genetics Inc.), Cytel Corp., Synbiotics Corp., and Murex Corp. (Cambridge U.K.). Additionally, Ms. Johnson served as Assistant Director with the Center for Devices and Radiological Health at the U.S. Food and Drug Administration. Ms. Johnson is also presently on the Board of Directors of MorphoSys AG, one of the oldest biotechnology companies in Europe. Ms. Johnson received an M.B.A. from Loyola University Maryland, her M.S. in Clinical Microbiology from the Hahnemann Medical School, and her B.S. in Microbiology from the University of Maryland. About Exagen Inc. Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. Exagen has developed and is commercializing a portfolio of innovative testing products under its AVISE® brand, several of which are based on its proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology. Exagen’s goal is to enable rheumatologists to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including SLE and rheumatoid arthritis. Exagen’s model of integrating testing products and therapeutics positions Exagen to offer targeted solutions to rheumatologists and, ultimately, better serve patients. For more information, please visit  www.Exagen.com . CONTACTS:

ProQuest Investments Investments

104 Investments

ProQuest Investments has made 104 investments. Their latest investment was in Adastra Pharmaceuticals as part of their Series E on April 4, 2019.

CBI Logo

ProQuest Investments Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

4/24/2019

Series E

Adastra Pharmaceuticals

$2.25M

No

1

11/10/2016

Series H

ReVision Optics

$32M

No

8

8/4/2015

Series H

Mevion Medical Systems

$200M

No

3

12/2/2013

Series B - II

Subscribe to see more

$99M

Subscribe to see more

10

10/30/2013

Series C

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/24/2019

11/10/2016

8/4/2015

12/2/2013

10/30/2013

Round

Series E

Series H

Series H

Series B - II

Series C

Company

Adastra Pharmaceuticals

ReVision Optics

Mevion Medical Systems

Subscribe to see more

Subscribe to see more

Amount

$2.25M

$32M

$200M

$99M

$99M

New?

No

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

8

3

10

10

ProQuest Investments Portfolio Exits

32 Portfolio Exits

ProQuest Investments has 32 portfolio exits. Their latest portfolio exit was SomaLogic on March 29, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

3/29/2021

Acq - Pending

$99M

3

6/28/2017

IPO

$99M

Public

2

1/27/2015

IPO

$99M

Public

2

12/2/2014

Acq - P2P

Subscribe to see more

$99M

Subscribe to see more

10

7/24/2014

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

3/29/2021

6/28/2017

1/27/2015

12/2/2014

7/24/2014

Exit

Acq - Pending

IPO

IPO

Acq - P2P

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Public

Subscribe to see more

Subscribe to see more

Sources

3

2

2

10

10

ProQuest Investments Acquisitions

1 Acquisition

ProQuest Investments acquired 1 company. Their latest acquisition was Bigchalk.com on December 23, 2002.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

12/23/2002

Series B

$99M

$99.29M

Acquired

Date

12/23/2002

Investment Stage

Series B

Companies

Valuation

$99M

Total Funding

$99.29M

Note

Acquired

Sources

ProQuest Investments Fund History

4 Fund Histories

ProQuest Investments has 4 funds, including ProQuest Investments IV LP.

Closing Date

Fund

Fund Type

Status

Amount

Sources

12/8/2006

ProQuest Investments IV LP

Early-Stage Venture Capital

Closed

$425M

1

3/1/2005

ProQuest Investments III LP

Subscribe to see more

Subscribe to see more

$99M

10

3/31/2002

ProQuest Investments II LP

Subscribe to see more

Subscribe to see more

$99M

10

5/13/1999

ProQuest Investments I LP

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

12/8/2006

3/1/2005

3/31/2002

5/13/1999

Fund

ProQuest Investments IV LP

ProQuest Investments III LP

ProQuest Investments II LP

ProQuest Investments I LP

Fund Type

Early-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Closed

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$425M

$99M

$99M

$99M

Sources

1

10

10

10

ProQuest Investments Team

4 Team Members

ProQuest Investments has 4 team members, including current Chief Financial Officer, Pasquale Deangelis.

Name

Work History

Title

Status

Pasquale Deangelis

Chief Financial Officer

Current

Christopher Thompson

Controller

Current

Jay Moorin

General Partner

Current

Alain B. Schreiber

General Partner

Current

Name

Pasquale Deangelis

Christopher Thompson

Jay Moorin

Alain B. Schreiber

Work History

Title

Chief Financial Officer

Controller

General Partner

General Partner

Status

Current

Current

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.